Title |
Interventions for HIV‐associated nephropathy
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2013
|
DOI | 10.1002/14651858.cd007183.pub3 |
Pubmed ID | |
Authors |
Ismail Yahaya, Olalekan A Uthman, Muhammed Mubashir B Uthman |
Abstract |
Human immunodeficiency virus-associated nephropathy (HIVAN) is the most common cause of end stage kidney disease (ESKD) in human immunodeficiency virus-1 (HIV-1) serotype patients and it mostly affects patients of African descent. It rapidly progresses to ESKD if untreated. The goal of treatment is directed toward reducing HIV-1 replication and/or slowing the progression of chronic kidney disease. The following pharmacological agents have been used for the treatment of HIVAN: antiretroviral therapy, angiotensin-converting enzyme inhibitors (ACEi), steroids and recently cyclosporin. Despite this, the effect of each intervention is yet to be evaluated. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 137 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 25 | 18% |
Researcher | 12 | 9% |
Student > Postgraduate | 11 | 8% |
Student > Bachelor | 11 | 8% |
Student > Ph. D. Student | 11 | 8% |
Other | 18 | 13% |
Unknown | 49 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 50 | 36% |
Nursing and Health Professions | 11 | 8% |
Biochemistry, Genetics and Molecular Biology | 3 | 2% |
Immunology and Microbiology | 3 | 2% |
Social Sciences | 3 | 2% |
Other | 14 | 10% |
Unknown | 53 | 39% |